| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Galera Therapeutics, Inc. | Chief Commercial Officer | Common Stock | 11,000 | $24,717 | $2.25 | 16 Mar 2023 | Direct |
| Galera Therapeutics, Inc. | Chief Commercial Officer | Stock Option (Right to Buy) | 135,000 | 25 Feb 2023 | Direct | ||
| Lyell Immunopharma, Inc. | Director | Option (right to buy) | 13,000 | 09 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc. | 09 Jun 2025 | 1 | $0 | 4 | Director | 11 Jun 2025, 17:48 |
| LYEL | Lyell Immunopharma, Inc. | 09 Jun 2025 | 0 | $0 | 3 | Director | 11 Jun 2025, 17:42 |
| GRTX | Galera Therapeutics, Inc. | 16 Mar 2023 | 1 | +$24,717 | 4 | Chief Commercial Officer | 20 Mar 2023, 16:05 |
| GRTX | Galera Therapeutics, Inc. | 25 Feb 2023 | 1 | $0 | 4 | Chief Commercial Officer | 28 Feb 2023, 17:56 |
| GRTX | Galera Therapeutics, Inc. | 28 Feb 2022 | 1 | $0 | 4 | Chief Commercial Officer | 02 Mar 2022, 15:05 |
| GRTX | Galera Therapeutics, Inc. | 08 Oct 2021 | 1 | $0 | 4 | Chief Commercial Officer | 12 Oct 2021, 20:23 |
| GRTX | Galera Therapeutics, Inc. | 08 Oct 2021 | 0 | $0 | 3 | Chief Commercial Officer | 12 Oct 2021, 20:18 |